MJ Holdings Past Earnings Performance
Past criteria checks 0/6
MJ Holdings has been growing earnings at an average annual rate of 82.9%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 147.5% per year.
Key information
82.9%
Earnings growth rate
82.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -147.5% |
| Return on equity | -71.6% |
| Net Margin | 442.0% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How MJ Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -1 | 1 | 0 |
| 30 Jun 23 | 0 | -4 | 3 | 0 |
| 31 Mar 23 | 0 | -4 | 2 | 0 |
| 31 Dec 22 | 0 | -5 | 4 | 0 |
| 30 Sep 22 | 0 | -6 | 7 | 0 |
| 30 Jun 22 | 0 | -4 | 5 | 0 |
| 31 Mar 22 | 0 | -5 | 7 | 0 |
| 31 Dec 21 | 0 | 4 | 8 | 0 |
| 30 Sep 21 | 1 | 4 | 7 | 0 |
| 30 Jun 21 | 1 | 4 | 6 | 0 |
| 31 Mar 21 | 1 | 4 | 5 | 0 |
| 31 Dec 20 | 1 | -4 | 3 | 0 |
| 30 Sep 20 | 0 | -6 | 4 | 0 |
| 30 Jun 20 | 1 | -8 | 6 | 0 |
| 31 Mar 20 | 1 | -9 | 7 | 0 |
| 31 Dec 19 | 1 | -8 | 7 | 0 |
| 30 Sep 19 | 1 | -7 | 7 | 0 |
| 30 Jun 19 | 1 | -9 | 6 | 0 |
| 31 Mar 19 | 1 | -8 | 5 | 0 |
| 31 Dec 18 | 0 | -8 | 5 | 0 |
| 30 Sep 18 | 0 | -5 | 2 | 0 |
| 30 Jun 18 | 0 | -1 | 1 | 0 |
| 31 Mar 18 | 0 | -1 | 0 | 0 |
Quality Earnings: MJNE is currently unprofitable.
Growing Profit Margin: MJNE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if MJNE's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare MJNE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MJNE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: MJNE has a negative Return on Equity (-71.59%), as it is currently unprofitable.